Literature DB >> 29089414

Flow diversion for anterior choroidal artery (AChA) aneurysms: a multi-institutional experience.

Visish M Srinivasan1, Michael George Zaki Ghali1, Jacob Cherian1, Maxim Mokin2, Ajit S Puri3, Ramesh Grandhi4, Stephen R Chen5, Jeremiah N Johnson1, Peter Kan1.   

Abstract

BACKGROUND: Anterior choroidal artery (AChA) aneurysms represent a small subset of cerebral aneurysms. The Pipeline Embolization Device (PED) has been successfully applied to various aneurysms of the supraclinoid internal carotid artery (ICA). The treatment of these aneurysms requires special attention due to the eloquent territory supplied by the AChA. We report the largest and first dedicated series of flow diversion treatment of AChA aneurysms.
METHODS: Four institutional neurointerventional databases were reviewed for cases of intracranial aneurysms treated with PED. Patient and aneurysm data as well as angiographic imaging were reviewed for all cases of AChA aneurysms treated with PED. AChA aneurysms were defined as aneurysms distal to the AChA and proximal to the ICA terminus, with or without the incorporation of the AChA.
RESULTS: Eighteen AChA aneurysms were treated during the study period. All aneurysms were successfully treated with a mean follow-up of 19.1 months. The large majority of aneurysms (15/18, 83.3%) were completely obliterated. No patients suffered from intra- or post-procedural complications. A1 stenosis was a common occurrence, seen in 10 of 16 (62.5%) covered anterior cerebral arteries (ACAs), although all were asymptomatic. All AChAs remained patent at last follow-up.
CONCLUSIONS: The PED can be used successfully in AChA aneurysms with a good safety and efficacy profile. All AChAs remained patent. Collateral flow networks, especially for the ACA, affect long-term branch vessel patency. Treatment with PED for AChA aneurysms appears to be a reasonable option to consider and should be evaluated in a larger cohort. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  aneurysm; angiography; artery; flow diverter; hemorrhage

Mesh:

Substances:

Year:  2017        PMID: 29089414     DOI: 10.1136/neurintsurg-2017-013466

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  6 in total

1.  Patency of anterior choroidal artery after flow diverter deployment with assessment of magnetic resonance imaging follow-up.

Authors:  Takashi Fujii; Hidenori Oishi; Kohsuke Teranishi; Kenji Yatomi; Munetaka Yamamoto; Hajime Arai
Journal:  Neuroradiol J       Date:  2018-12-03

2.  A New Classification of Anterior Choroidal Artery Aneurysms and Its Clinical Application.

Authors:  Yu Duan; Xuanfeng Qin; Qinqzhu An; Yikui Liu; Jian Li; Gong Chen
Journal:  Front Aging Neurosci       Date:  2021-03-15       Impact factor: 5.750

3.  Delayed Occlusion of the Anterior Choroidal Artery Following Flow Diverter Stent Deployment for Unruptured Aneurysm: A Case Report and Literature Review.

Authors:  Hisayuki Hosoo; Wataro Tsuruta; Shogo Dofuku; Takayuki Hara; Eiichi Ishikawa; Yuji Matsumaru
Journal:  NMC Case Rep J       Date:  2021-06-05

4.  Endovascular Treatment and Angiographic Characteristics of Aneurysms at the Origin of the Anterior Choroidal Artery.

Authors:  Yiheng Wang; Jinlu Yu
Journal:  Front Neurol       Date:  2022-03-14       Impact factor: 4.003

Review 5.  Anterior Choroidal Artery Aneurysms: Influence of Regional Microsurgical Anatomy on Safety of Endovascular Treatment.

Authors:  Michael George Zaki Ghali; Visish M Srinivasan; Kathryn M Wagner; Sandi Lam; Jeremiah N Johnson; Peter Kan
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2018-03-31

6.  Points to consider when evaluating three-dimensional digital subtraction angiography of intracranial aneurysms and their effects on treatment

Authors:  İsmail Yardımcıoğlu; Yılmaz Önal; Murat Velioğlu; Hakkı Muammer Karakaş
Journal:  Turk J Med Sci       Date:  2021-06-28       Impact factor: 0.973

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.